Sector News

ConvaTec strengthens its board

August 15, 2017
Life sciences

ConvaTec Group has appointed Dr Regina Benjamin and Margaret Ewing as non-executive directors with immediate effect.

Benjamin was United States surgeon general from 2009 – 2013 and is currently a non-executive director of Diplomat Pharmacy, Kaiser Foundation Hospitals and Health Plan, and Ascension Hospital System. She is a former non-executive director of Alere.

From 1992-2004 she served on the board of the Medical Association of Alabama, and in 1995, became the first young physician to be elected to the American Medical Association Board of Trustees. In 2008, she chaired the Federation of State Medical Licensing Boards.

Benjamin is CEO and practising physician at the Bayou La Batre Rural Health Clinic in Alabama, which she founded in 1990 and holds an endowed chair in Public Health Sciences at Xavier University of Louisiana. She will immediately join the corporate responsibility committee.

Ewing is currently a trustee of the board and chairman of the finance and audit committee of Great Ormond Street Hospital Children’s Charity. She is also the independent external member of the audit committee of the Lawn Tennis Association.

Ewing was previously a non-executive director of Standard Chartered, Whitbread and the Confederation of British Industry and the independent external member of the audit committee of John Lewis Partnership.

She was a corporate finance partner of Deloitte LLP between 1987-1999, returning to Deloitte in 2007 as a senior partner and retiring from the firm in 2012.

During the period 2007-2012 Mrs Ewing was vice-chairman and a member of the firm’s executive committee and the board, senior partner of the London practice and latterly managing partner for public policy, quality and risk.

Ewing was group chief financial officer of Trinity Mirror from 2000-2002 and of BAA plc from 2002-2006. She was also a member of the financial reporting review panel between 2011-2014. She will immediately join the audit and risk committee and corporate responsibility committee.

It was previously announced that Dr Raj Shah would be leaving the board of ConvaTec on 8 September 2017 following the reduction by Nordic Capital of its shareholding in the company.

Dr Ros Rivaz, who was appointed a non-executive director of the company on 21 June , will immediately join the nominations and remuneration committees in place of Shah.

Chairman Sir Christopher Gent said: “I am delighted to announce two appointments of individuals who bring a wealth of experience and knowledge to the Board.

“Also with the appointments of Regina and Margaret, we have fulfilled our promise to shareholders that we would appoint a Board which would comprise a majority of independent Directors and which would reflect the requirements and advantages of gender diversity.

“We look forward to benefiting from their contribution to the future success of the Company.”

Source: StockMarketWire

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.